Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI (STRENGTH)
Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI (STRENGTH)
Sponsor: European Cardiovascular Research Center
A NA clinical study on Acute Kidney Injury and Cardiovascular Disease, this trial is ongoing. The trial is conducted by European Cardiovascular Research Center and has accumulated 7 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Oct 2018 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Cardiovascular Research Center
- RenalGuard Solutions, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .